This site is intended only for healthcare professionals resident in the United Kingdom
Sign in
Sign In or Register
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

About

Prescribing Information for Bavencio® (avelumab) + axitinib aRCC click here or ​​​​​​​Bavencio® (avelumab) MCC & UC click here. Adverse event reporting information can be found at the bottom of the page.
​​​​​​​​​​​​Welcome. Find out more about
BAVENCIO® (avelumab)
​​​​​​​Merck Serono Ltd are the marketing authorisation holder for Bavencio®. This medicine is a Merck-Pfizer co-promote.

BAVENCIO® is a human IgG1 anti-PD-L1 antibody that removes the suppressive effects of PD-L1 on cytotoxic CD8+ T-cells, restoring their anti-tumour effects.1 It is licensed for the following indications:

Advanced renal cell carcinoma (aRCC)

BAVENCIO® (avelumab) in combination with axitinib is indicated for the first-line treatment of adult patients with aRCC.1

Learn more about BAVENCIO® in aRCC

Urothelial carcinoma (UC) ​​​​​​​

BAVENCIO® (avelumab) is indicated
as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic UC who are progression-free following platinum-based chemotherapy.1

Learn more about BAVENCIO® in UC

Metastatic Merkel cell carcinoma (mMCC)

BAVENCIO® (avelumab) is indicated as monotherapy for the treatment of adult patients with mMCC.1

Learn more about BAVENCIO® in mMCC


​​​​​​​Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Merck Serono Limited on 0208 818 7373 (email: [email protected])

Abbreviations:
aRCC : Advanced renal cell carcinoma, IgG1 : Immunoglobulin G1, mMCC : metastatic Merkel cell carcinoma, PD-L1 : programmed death-ligand 1, UC : Urothelial carcinoma 

References
  1. BAVENCIO® (avelumab) Summary of Product Characteristics for Great Britain: www.medicines.org.uk. BAVENCIO® (avelumab) Summary of Product Characteristics for Northern Ireland: www.emcmedicines.com​​​​​​​
PP-BAV-GBR-1410. May 2022

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-3863. November 2021

Yes

No

OK, We will need you to sign in before we can determine if you are aligned with a Pfizer promotional colleague.This is an interstitial message to prompt a HCP before they login.

If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.

Would you like to register or sign in now?